A special limited webinar series focused on Alzheimer's disease and related dementias (ADRD) across populations.
In the US, ADRD are the seventh leading cause of death among all adults and the sixth leading cause for adults 65 years or older (CDC, 2024). Pre-clinical biomarkers of ADRD are an emerging area of interest in the field of geriatric medicine. Known biomarkers include tau and beta-amyloid proteins in the cerebrospinal fluid and plasma and amyloid plaques and tau tangles in the brain (National Institute on Aging, 2022). Identifying these initial signals could help to gauge a patient’s risk of developing dementia or to establish a pre-symptomatic diagnosis (Dubois et al., 2023). However, not all populations are benefiting equally from ADRD advancements. Current tests for biomarkers, including CT, MRI, and PET scans and lumbar punctures, are time and resource intensive. I
n this webinar, expert panelists will discuss barriers and opportunities for early ADRD detection and diagnosis across populations.
Learning Objectives:
-Discuss the use of ADRD biomarkers in ADRD diagnosis and treatment
-Compare ADRD biomarker advances across populations
-Explain the challenges of using ADRD biomarkers
-Describe social determinants of health limiting access to biomarker tests
-Identify opportunities for more patients to benefit from ADRD early diagnosis
In support of improving patient care, this activity has been planned and implemented by the American Psychiatric Association (APA). APA is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The APA designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
More Info